PolarityTE (COOL) Misses Q3 EPS by 26c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cantor Fitzgerald Maintains Bullish View on PolarityTE (COOL) Post Q3
September 12, 2018 10:36 AM EDTCantor Fitzgerald analyst Elemer Piros reiterated an Overweight rating and $65 price target on PolarityTE (NASDAQ: COOL) following Q3 results.
Piros notes additional clinical outcomes data will be presented at the American Society of Plastic Surgeons Conference, taking place from Sept.28-Oct.1 in Chicago.
PolarityTE remains focused on the commercialization of... More
PolarityTE (COOL) said it's not being investigated by the SEC - Bloomberg
September 12, 2018 8:53 AM EDTOn its call, PolarityTE (NASDAQ: COOL) said it's not being investigated by the SEC - Bloomberg
... MorePre-Open Movers 09/10: (FRED) (ECYT) (TLRY) Higher; (COOL) (EXEL) (BABA) Lower (more...)
September 10, 2018 9:14 AM EDTToday's Pre-Open Movers
Fred's (NASDAQ: FRED) 42.5% HIGHER; the company and Walgreens (NYSE: WBA) entered into a definitive asset purchase agreement, pursuant to which Walgreens will acquire pharmacy patient prescription files and related pharmacy inventory of 185 Freds stores located across 10 Southeastern states.
Endocyte, Inc. (NASDAQ: ECYT) 15.9% HIGHER; announced that following a meeting with the U.S. Food and Drug Administration (FDA), it was determined that rPFS is an appropriate efficacy endpoint in the... More
PolarityTE (COOL) Issues Statement Regarding John Stetson and his Termination (Earlier)
September 10, 2018 8:45 AM EDTPolarityTE, Inc. (Nasdaq: COOL), a commercial-stage biotechnology and regenerative biomaterials company, today issued the following statement regarding the recent SEC complaint against Mr. John Stetson:
PolarityTE's management team and Board of Directors are committed to upholding the highest standards of... More
